Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

2019 February 26 - 28
Hilton Tokyo Bay Hotel,
Tokyo, Japan

The Only Event in Asia Providing the Latest Science, Technology and Partners to Accelerate Antibody & Protein Therapies, ADCs, Bispecifics and Immuno-Oncology

World-renowned scientists sharing the latest technologies, R&D and clinical data to fast-track your next-generation therapeutics towards commercial success

White Paper

ANTIBODIES TO WATCH 2019 PREVIEW: Download the highly-anticipated preview of antibody therapeutics granted a first approval this year, those in regulatory review, and those that might enter regulatory review in the next ~9 months.

NEW TECHNOLOGIES, R&D ADVANCES AND CLINICAL DATA TO HELP YOU FAST-TRACK NEXT-GENERATION THERAPEUTICS TO MARKET

Improve Antibody “Drug-Like” Properties
  • Gain new strategies for antibody design, engineering and selection to help you improve the properties of your antibody drugs
  • Find new delivery strategies to help you overcome biological barriers of antibodies
  • Learn about the latest advances and challenges in Immuno-oncology drug development, including the clinical status of several new drugs
Scientific Case Studies with New Data
  • Hear case studies of Antibody-Drug Conjugate (ADC) development programs including presentations from Daiichi Sankyo, AbbVie Stemcentryx and more
  • Find out about the latest preclinical and clinical results from novel therapeutics and learn about the challenges experienced and lessons learned
  • Gain a competitive for your new therapeutic by learning how to create bispecific antibodies and multi-functional biologics with better properties than existing therapeutics
Event Highlights
  • Pre-conference workshop to help you accelerate your therapeutic pipeline: Enabling Technologies in Antibody Discovery and Therapeutic Development
  • Share your own research and get feedback from fellow attendees by presenting a scientific poster. All registered attendees may reserve a posterboard.
  • Make antibody contacts from around the world by participating in the networking activities including the partnering app, Tokyo networking dinner, cocktail receptions and more.

Get Global Recognition of Your Work by Presenting a Poster at Antibody Engineering & Therapeutics


Why Should You Present a Poster?

  1. FOCUSED DISCUSSIONS: Posters offer the opportunity to engage with others also interested in the same subject and application as yourself which could potentially lead to future collaboration. 
  2. RECEIVE IMPARTIAL CRITIQUES: An insightful, impartial discussion of your work by a peer can often provide ideas for improving your work downstream.
  3. SHARPEN YOUR PRESENTATION SKILLS: Presenting a poster enables you to explain a concept in different ways to see which method is most well received and practice your visual and oral presentations.
  4. HONE YOUR IDEAS: A poster is ideal for early stages of the research, when you may not have much more than an idea, and you stand to benefit a lot from discussing your idea with other researchers from the same field.

Meet the Esteemed Scientific Advisory Board

  • Tomoyuki Igawa, Ph.D., CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore
  • Osamu Sato, Ph.D., General Manager, Sakigake-Projects; DS-5141 and DS-1647 and Senior Executive Advisor for Head of R&D, Daiichi Sankyo Co., Ltd., Japan
  • Sai Reddy, Ph.D., Assistant Professor,  ETH Zurich, Switzerland
  • Yuji Ito, Ph.D., Professor, Department of Chemistry and Bioscience, Graduate School of Science and Engineering, Kagoshima University, Japan
  • Jijie Gu, Ph.D., Head of Target Validation, Immunology Discovery, Abbvie Cambridge Research Center, USA
  • Yong-Sung Kim, Ph.D., Professor, Departments of Molecular Science and Technology, and Applied Chemistry and Biological Engineering, Ajou University, South Korea
  • H. Kaspar Binz, Ph.D., Vice President and Co-Founder, Molecular Partners AG, Switzerland
  • Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica, USA
  • Qing Li, Ph.D., Scientist I, MedImmune, USA
  • Karthik Viswanathan, Director, Research, Visterra, Inc., USA
  • Chengbin Wu, Ph.D., Chief Executive Officer, Shanghai EpimAb Biotherapeutics Inc., China
  • Kouhei Tsumoto, Ph.D., Professor and Director, Department of Bioengineering, Department of Chemistry and Biotechnology, The University of Tokyo, Japan